Proteolysis of IGFBP-3 may be a common regulatory mechanism of IGF action in vivo.
GEORGE LAMSON(Stanford University), R G Rosenfeld(Laboratório Interinstitucional de e-Astronomia), Linda C. Giudice(University of California, San Francisco), Youngman Oh(Virginia Commonwealth University), Fang Liu(Stanford University), Raymond L. Hintz(Endocrine Society), Sharron Gargosky(Stanford University), P. Cohen(Stanford University), Kristin F. Wilson(Cornell University), Hermann L. Müller(Klinikum Oldenburg)
PubMed
March 1, 1993
Cited by 80
Related Papers
Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations
|Nature Communications|2015|542
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
|New England Journal of Medicine|2017|492
Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition
|Journal of Biological Chemistry|1993|477
Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth.
|The Journal of Clinical Endocrinology & Metabolism|1995|365
Recommendations for the Diagnosis and Management of Turner Syndrome<sup>1</sup>
|The Journal of Clinical Endocrinology & Metabolism|2001|354